Aerium

Aerium Therapeutics Advances Next Generation Antibodies to Protect Immunocompromised Persons Against COVID-19

Retrieved on: 
Wednesday, October 4, 2023
COVID-19, Research, Infectious Diseases, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Aerium, Infection, UNC School of Medicine, RBD, Vaccination, Rockefeller University, SARS-CoV-2, Hook effect, Hope, Person, CHUV, Global Health, Death, EPFL, Immunodeficiency, Fred Hutchinson Cancer Research Center, Therapy, Vaccine, ACE2, Lausanne University Hospital, Tropical Islands Resort, Medicine

AER004 was discovered by Michel Nussenzweig at Rockefeller University and also blocks the RBD in a complementary manner to AER003.

Key Points: 
  • AER004 was discovered by Michel Nussenzweig at Rockefeller University and also blocks the RBD in a complementary manner to AER003.
  • Aerium is pursuing a mAb combination strategy to defend against future viral evolution.
  • Aerium is also initiating development of AER005 for potential inclusion in a future product.
  • The mAbs have been modified to provide long-acting protection and exhibit potent and consistent activity against all previous and predominantly circulating variants.

Tubulis Appoints Seasoned ADC Expert Björn Hock as Chief Development Officer

Retrieved on: 
Thursday, February 16, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Aerium, Limited partnership, CDO, Therapy, ADC, Drug development, Patient, Tropical Islands Resort, Merck, Ferring Pharmaceuticals, Spacecraft, Doctor of Philosophy, Management, Biochemistry, Rida al-Tubuly

Tubulis today announced the appointment of Björn Hock, PhD, as Chief Development Officer (CDO) to further strengthen its leadership team with a seasoned drug development expert.

Key Points: 
  • Tubulis today announced the appointment of Björn Hock, PhD, as Chief Development Officer (CDO) to further strengthen its leadership team with a seasoned drug development expert.
  • At Tubulis, he will be responsible for defining preclinical development strategies for the company’s current drug candidates in oncology to rapidly achieve IND-readiness.
  • “We are grateful for his extended commitment in supporting us as Chief Development Officer.
  • Over the course of his career, Dr. Hock has led the successful development of several platform technologies and therapeutic programs from concept to lead candidate stage.

PharmaVentures advises Lausanne Hospital (CHUV) and EPFL on their collaboration and founding of Aerium Therapeutics to develop their highly potent SARS-CoV-2 antibodies

Retrieved on: 
Thursday, March 24, 2022
Aerium, Therapy, Vaccination, Omega, Lausanne University Hospital, Volatile organic compound, EPFL, Research, Delta, CEO, Severe acute respiratory syndrome coronavirus 2, Immunology, CHUV, Omicron, Neutralizing antibody, COVID-19, Series, Patient, Antibody, Vaccine, Medicine

Aerium Therapeutics is focused on discovering and developing novel monoclonal antibodies (mAbs) and antiviral treatments against SARS-CoV-2.

Key Points: 
  • Aerium Therapeutics is focused on discovering and developing novel monoclonal antibodies (mAbs) and antiviral treatments against SARS-CoV-2.
  • The company has recently emerged with substantial Series A financial backing by the founding investor Omega Funds with the participation of F-Prime Capital.
  • Aerium was seeded and incubated by Omega Funds in 2021 and started in collaboration with its two scientific founders, Dr. Giuseppe Pantaleo (CHUV) and Dr. Didier Trono (EPFL) in Switzerland.
  • In addition to its antiviral properties, the antibody has been designed to provide protection to those patients most vulnerable.

PharmaVentures advises Lausanne Hospital (CHUV) and EPFL on their collaboration and founding of Aerium Therapeutics to develop their highly potent SARS-CoV-2 antibodies

Retrieved on: 
Thursday, March 24, 2022
Aerium, Therapy, Vaccination, Omega, Lausanne University Hospital, Volatile organic compound, EPFL, Research, Delta, CEO, Severe acute respiratory syndrome coronavirus 2, Immunology, CHUV, Omicron, Neutralizing antibody, COVID-19, Series, Patient, Antibody, Vaccine, Medicine

Aerium Therapeutics is focused on discovering and developing novel monoclonal antibodies (mAbs) and antiviral treatments against SARS-CoV-2.

Key Points: 
  • Aerium Therapeutics is focused on discovering and developing novel monoclonal antibodies (mAbs) and antiviral treatments against SARS-CoV-2.
  • The company has recently emerged with substantial Series A financial backing by the founding investor Omega Funds with the participation of F-Prime Capital.
  • Aerium was seeded and incubated by Omega Funds in 2021 and started in collaboration with its two scientific founders, Dr. Giuseppe Pantaleo (CHUV) and Dr. Didier Trono (EPFL) in Switzerland.
  • In addition to its antiviral properties, the antibody has been designed to provide protection to those patients most vulnerable.

Aerium Therapeutics launches to develop novel therapeutics against COVID-19 and future pandemic threats

Retrieved on: 
Tuesday, March 22, 2022
Aerium, Pantaleo, Therapy, Vaccination, DRS, Degenerative disease, Medtech, Leadership, Multimedia, Board, Omega, Health care, Vaccine, Volatile organic compound, EPFL, Research, White, Delta, Capital, Severe acute respiratory syndrome coronavirus 2, Precision medicine, CEO, AstraZeneca, Immunology, Merck & Co., White House, CHUV, Omicron, Technology, Neutralizing antibody, Virology, COVID-19, Trono, Montreux Healthcare Fund, Series, BioRxiv, Bill & Melinda Gates Foundation, FDA, Director, History, Partnership, Antibody, Financial services, Management, Pharmaceutical industry, Medicine, Takeda, Coalition for Epidemic Preparedness Innovations, Pfizer, Ultragenyx, Tropical Islands Resort, Genetics

While we are initially assisting populations vulnerable to COVID-19 in the prophylactic and therapeutic settings, our overall vision is to develop effective therapeutics against not just existing but also future epidemic and pandemic threats."

Key Points: 
  • While we are initially assisting populations vulnerable to COVID-19 in the prophylactic and therapeutic settings, our overall vision is to develop effective therapeutics against not just existing but also future epidemic and pandemic threats."
  • Aerium Therapeutics has assembled a growing team of proven life science and enterprise leaders including:
    CEO Rajeev Venkayya, M.D.
  • Aerium Therapeutics is dedicated to epidemic and pandemic preparedness through the discovery and development of antibodies and small molecule antivirals against SARS-CoV-2 and other epidemic and pandemic threats.
  • The company plans to expand its pipeline to antiviral therapeutics in late 2022 and will broaden its focus to other epidemic and pandemic threats in the future.